- Home
- ONEG vs CYCN Comparison
ONEG vs CYCN Comparison
Compare ONEG & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | CYCN |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 16.6M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ONEG | CYCN |
|---|---|---|
| Price | $1.04 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.0K | ★ 90.6K |
| Earning Date | 01-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $0.72 | $1.03 |
| 52 Week High | $14.95 | $8.48 |
Technical Indicators
Market Signals| Indicator | ONEG | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 41.06 |
| Support Level | $1.00 | $3.04 |
| Resistance Level | $1.06 | $3.42 |
| Average True Range (ATR) | 0.02 | 0.49 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 65.87 | 23.67 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction projects include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.